Extended Hormone Therapy Doesn’t Help Some Prostate Cancer Patients: Study

Shorter-course treatment as effective for those with intermediate-risk disease, oncologist says
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Authors: Tags: Endocrinology, Gynecology, Oncology, Reproductive Medicine, News, Source Type: news

Related Links:

ConclusionsNon-tissue diagnosis of prostate cancer, while rare, is not outside normal clinical practice and is strongly associated with advanced patient age, higher clinical stage, multiple comorbidities, and very high PSA levels.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
ConclusionCombined HDR-B/EBRT for the treatment of clinically localized prostate cancer provides superb clinical outcomes with excellent 5-year bRFS, dMFS, OS, and late GI/GU toxicity rates.
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research
ngione Mario Pulvirenti Antonino Romeo Ugo De Giorgi The therapeutic landscape of prostate cancer has expanded rapidly over the past 10 years, and there is now an even greater need to understand the biological mechanisms of resistance and to develop noninvasive biomarkers to guide treatment. The androgen receptor (AR) is known to be involved in the pathogenesis and progression of prostate cancer. Recently, highly sensitive next-generation sequencing and PCR-based methods for analyzing androgen receptor gene (AR) copy numbers (CN) and mutations in plasma were established in cell-free DNA (cfDNA) of patients with c...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Condition:   Metastatic Castration-resistent Prostate Cancer Interventions:   Drug: Docetaxel;   Drug: Abiraterone Acetate or Enzalutamide Sponsor:   National Cancer Institute, Naples Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS.—: Our understanding of neuroendocrine tumors of the prostate classification and diagnosis continues to evolve. These advances benefit the risk stratification and management of prostate cancer. PMID: 31644322 [PubMed - as supplied by publisher]
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Tags: Arch Pathol Lab Med Source Type: research
Conditions:   Positive Lymph Node;   Prostate Adenocarcinoma;   PSA Level Greater Than Zero;   Stage I Prostate Cancer AJCC v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC  v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage I...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Endocrinology | Hormonal Therapy | Hormones | Prostate Cancer | Study